Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 10 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 10 21.
ORTHO TRI-CYCLEN 21 vs ORTHO-NOVUM 10-21
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining, reducing sperm penetration and implantation.
Prevention of pregnancy
Prevention of pregnancyTreatment of menorrhagiaTreatment of dysmenorrheaRegulation of menstrual cyclesEmergency contraception (off-label)
One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.
1 tablet (1 mg norethindrone, 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of no tablets.
None Documented
None Documented
Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Norethindrone 5-14 hours (mean 8 hours), ethinyl estradiol 7-20 hours (mean 13 hours). Steady-state achieved in 5-10 days.
Norgestimate: hydrolyzed to norelgestromin and norgestrel; metabolized by CYP3A4, CYP2C9, and CYP2C19. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation.
Hepatic via cytochrome P450 3A4 (CYP3A4) for norethindrone and ethinyl estradiol; first-pass metabolism; enterohepatic recirculation; elimination as glucuronide and sulfate conjugates in urine and feces.
Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Renal approximately 50-60% as metabolites, biliary/fecal approximately 30-40% as metabolites and unchanged drug.
Norgestimate: ~99% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin; norethindrone (active metabolite) binds with similar high affinity.
Norethindrone: 90-95% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norgestimate: Vd ~6-8 L/kg; ethinyl estradiol: Vd ~3-5 L/kg. Large Vd indicates extensive tissue distribution including breast, uterine, and hepatic tissues; clinical relevance: potential for drug interactions (e.g., enzyme inducers).
Norethindrone: 4 L/kg; ethinyl estradiol: 2-4 L/kg; indicates extensive tissue distribution.
Oral: Norgestimate ~75% (first-pass metabolism limits bioavailability); ethinyl estradiol ~40-60% (substantial first-pass effect).
Oral: norethindrone 50-80%, ethinyl estradiol 40-60% due to first-pass metabolism.
No specific dose adjustment is provided in manufacturer labeling; use with caution in patients with renal impairment. GFR-based adjustments are not established.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (GFR <30 mL/min) due to lack of safety data.
Contraindicated in patients with hepatic disease or hepatocellular carcinoma. Child-Pugh class B or C: contraindicated. Child-Pugh class A: use with caution, no specific dose adjustment defined.
Contraindicated in Child-Pugh class B or C hepatic impairment. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment established.
Safety and efficacy established in postmenarchal females; dosing is same as adult: one tablet daily for 21 days. Weight-based dosing not applicable.
Not indicated for use in pediatric patients before menarche. Post-menarche: same adult dosing, 1 tablet orally once daily for 21 days, then 7 days off.
Not indicated for use in postmenopausal women. No specific considerations available.
Not indicated for use in postmenopausal women. Not recommended for elderly patients due to lack of efficacy and increased thrombotic risk.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
["Thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, stroke, myocardial infarction)","Hepatic disease (including hepatic adenoma or carcinoma)","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism disturbances","Headache (including migraine with focal symptoms)","Uterine bleeding irregularities"]
Increased risk of thromboembolic disorders (e.g., DVT, pulmonary embolism), myocardial infarction, stroke; hepatic neoplasia (benign and malignant); gallbladder disease; hypertension; glucose intolerance; elevated triglyceride levels; exacerbation of depression; fluid retention; headache; irregular bleeding; potential for decreased efficacy with concomitant enzyme-inducing drugs; instruct to report visual disturbances or migraine; discontinue if jaundice occurs; monitor for signs of thrombosis.
["Known or suspected pregnancy","Current or history of thromboembolic disorders (e.g., DVT, PE)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal genital bleeding","Hepatic adenoma or carcinoma, or active liver disease","Hypersensitivity to any component","Smoking in women over 35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with aura if >35 years","Major surgery with prolonged immobilization"]
Thrombophlebitis or thromboembolic disorders; history of DVT or PE; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; liver tumors (benign or malignant) or active liver disease; hypersensitivity to any component; age >35 years and smoking cigarettes; uncontrolled hypertension; diabetes with vascular involvement; migraine with focal aura; major surgery with prolonged immobilization.
Data Pending Review
Data Pending Review
No specific food restrictions; however, grapefruit juice may increase estrogen levels (minor interaction). Avoid St. John's wort, which can reduce contraceptive efficacy.
No significant food interactions. Grapefruit juice may increase estrogen levels but clinical relevance is minimal. Avoid excessive alcohol consumption due to potential liver strain. Maintain consistent dietary habits to reduce gastrointestinal side effects.
First trimester: Risk of congenital anomalies (limb defects, neural tube defects) based on case reports; overall risk low. Second/third trimester: Possible increased risk of intrauterine growth restriction and preterm birth. Postnatal: Potential for jaundice and transient hormonal effects in neonates.
Pregnancy category X. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second and third trimesters: associated with fetal adrenal suppression, virilization of female fetuses, and potential for long-term neurodevelopmental effects. Use contraindicated in pregnant women.
Contraindicated in breastfeeding due to estrogens reducing milk production and quality. Limited data; M/P ratio not established. Alternative methods preferred.
Excreted into breast milk in small amounts (M/P ratio approximately 0.5). May reduce milk production and composition. Use during breastfeeding not recommended; alternative contraception advised.
No dose adjustments needed as drug is contraindicated during pregnancy. Discontinue immediately upon confirmed pregnancy; pharmacokinetic changes not applicable.
Contraindicated in pregnancy; no dosing adjustments are applicable. Discontinue immediately if pregnancy occurs.
Category C
Category C
ORTHO TRI-CYCLEN 21 contains norgestimate and ethinyl estradiol; it is a triphasic oral contraceptive with varying hormone doses across 21 active pills. Its progestin component has low androgenicity, making it suitable for patients with acne or hirsutism. Monitor for thromboembolic risk, especially in smokers over 35. Missed pill management: if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception and consider emergency contraception.
ORTHO-NOVUM 10-21 (norethindrone 10 mg with ethinyl estradiol 21 mcg) 21-day regimen: breakthrough bleeding/spotting is common during first 3 cycles; encourage continuation. If a dose is missed, take as soon as remembered and use backup contraception for 7 days. Higher estrogen content increases thromboembolic risk; avoid in smokers >35 years. Monitor blood pressure and liver function at baseline and periodically.
Take one pill daily at the same time for 21 days, then 7 placebo pills.Use backup contraception (e.g., condoms) for the first 7 days of initial use.Common side effects: nausea, breast tenderness, breakthrough bleeding; these often improve after 2-3 cycles.Report signs of blood clots: leg pain/swelling, chest pain, sudden shortness of breath, severe headache.Smoking increases blood clot risk; do not smoke while using this medication.If severe vomiting or diarrhea occurs within 4 hours after taking a pill, consider it missed and follow missed pill instructions.
Take one tablet daily at the same time for 21 days, then 7 pill-free days.Use backup contraception (e.g., condoms) for the first 7 days of the first pack.If you miss a pill, take it as soon as you remember; if more than 24 hours, take last missed and use backup for 7 days.Common side effects include nausea, breast tenderness, spotting, and mood changes; they often improve within 3 months.Seek medical attention for severe leg pain, chest pain, shortness of breath, or severe headache.Do not smoke while taking this medication, especially if over 35 years old.